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ARDS = acute respiratory distress syndrome; ICD-9-CM = International Classification of Diseases, 9th Revision, Clinical Modifications; ICD-10 =
International Classification of Diseases, 10th Revision; ICU = intensive care unit.
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In 1991 a consensus of international experts was reached
that defined the syndrome of severe sepsis as the presence
of infection, a systemic inflammatory response, and acute
organ dysfunction [1]. Severe sepsis quickly became one of
the defining ‘diseases’ of intensive care. An explosion in our
understanding of the underlying pathophysiology led to a
profusion of large multicenter trials of prospective agents in
patients who met severe sepsis criteria. Entire tracks at
national and international intensive care meetings were
dedicated to sepsis, and, most recently, several intensive
care professional societies launched a public and clinician
educational effort, entitled the ‘Surviving Sepsis’ campaign
(www.survivingsepsis.org) [2–4].
Despite this huge investment of time, funding, and expertise
in severe sepsis, we were slower to understand some basic
epidemiologic and health services research questions, such
as population incidence, risk factors for the development and
progression of disease, long-term outcomes, costs of care,
and variation in practice patterns. This is now changing.
Three new articles published in Critical Care [5–7] add to an
expanding body of information on the epidemiology of severe
sepsis. These studies, together with several others reported
in the past few years, highlight several issues that are worthy
of further comment.
The three papers show the range of approaches to
estimating severe sepsis incidence and the difficulties that
arise in trying to compare results. The study conducted by
van Gestel and coworkers [7] is a carefully crafted analysis of
the prevalence of severe sepsis on 1 day (11 December
2001) in Dutch intensive care units (ICUs). Those
investigators reported an incidence rate of 0.54 cases/1000
population, and found that 11% of ICU admissions have
severe sepsis. The study nicely highlights the care required
when generating annual estimates from a short observation
period. Silva and colleagues [5] reported the results of a
prospective multicenter ICU screening study conducted in
Brazil over 9 months in 2001, in which they found an
incidence density of 57 per 1000 patient-days and 27.3% of
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Abstract
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ICU admissions. Flatten [6] reported on a retrospective
database study of hospital discharges using International
Classification of Diseases, 10th Revision (ICD-10) codes for
septicemia, estimating the incidence of sepsis (without acute
organ dysfunction) and severe sepsis (with acute organ
dysfunction) in a database that does not identify ICU use.
The incidence for severe sepsis was 0.30% of
hospitalizations and 0.47/1000 population. Summary results
for these studies and the other published studies of the
incidence of severe sepsis are shown in Table 1.
A number of other studies [8–11], like that reported by van
Gestel and coworkers [7], sampled over a short time frame.
In addition to the careful analysis needed to estimate
population incidence as shown by van Gestel and coworkers,
the results of such studies are susceptible to seasonal
considerations. Seasonal variation is likely to be particularly
problematic for severe sepsis arising from infections, such as
community-acquired pneumonia.
Although most studies used prospective screening for the
international consensus criteria for severe sepsis, the study
by Flatten [6] and two others [12,13] used coded data in
administrative databases to mirror the consensus criteria.
Because the administrative data were collected and coded
for other purposes, it is of paramount importance that
validation exercises be used to ascertain the validity of the
identification. Angus and coworkers [12] compared results
of their selection with hospitals reported in the study by
Sands and colleagues [9], and found similar incidence, ICU
use, site of infection, resource use, and mortality. Martin and
coworkers [13] conducted a validation study at a single
hospital and found an excellent positive predictive value
(97.7%) but a negative predicted value of only 80.0%.
Coupled with the overall detection rate achieved with the
criteria used by Martin and coworkers in their study
population, this negative predictive value yields a sensitivity
of only 18.8%, implying that the search missed four out of
five cases of severe sepsis. This is not surprising because
Martin and coworkers, like Flatten, looked only at a small
subset of codes for infection to define sepsis. ICD-9-CM
(International Classification of Diseases, 9th Revision,
Clinical Modification) codes prior to 2003 and ICD-10
codes, while using the term ‘sepsis’ in their indices and
names, do not have codes that correspond to the
consensus definitions of sepsis and severe sepsis. In 2003,
codes for sepsis and severe sepsis (995.91 for sepsis and
995.92 for severe sepsis) were introduced in the USA for
the first time. However, these codes are not yet in common
use. Correcting the findings reported by Martin and
colleagues for the poor sensitivity yields an overall incidence
of 4/1000 population for hospital severe sepsis – a result
close to that reported by Angus and coworkers [12].
Unfortunately, Flatten [6] did not include any validation
exercise, making it difficult to place that result in context with
other measurements. Finally, neither Flatten nor Martin and
colleagues reported findings that apply to ICU severe
sepsis, further limiting comparability.
Perhaps the most important confounder in our understanding
of the incidence of severe sepsis is that all our
measurements in the ICU relate not to the incidence of
severe sepsis but to its treated incidence. This is an
important distinction that has long been known in the cancer
community. There can be large differences between the
number of people with a cancer and the number being
treated in a given time period. Thus, cancer epidemiologists
distinguish between cancer prevalence, which is often
difficult to determine, and cancer treated prevalence.
Although an unknown incidence of severe sepsis might be
the same in all developed countries, the choices we make
regarding who to treat in hospital or admit to an ICU for
advanced life support would generate very different treated
incidence rates. To meet severe sepsis criteria, organ
dysfunction must be detected and treated. Because the
detection and treatment takes place predominantly in ICUs,
countries with fewer ICU beds will probably have lower
treated incidence rates. For example, an elderly patient who
develops a stroke, complicated by pneumonia, will not be
coded as having severe sepsis if she dies at home but will be
coded as having severe sepsis if intubated and admitted to
the ICU.
Most studies have expressed ‘incidence’ as the number of
cases per 100 ICU admissions. With the exception of two
studies, most reported rates of about 10 ± 4 cases/100 ICU
admissions. This rate is remarkably stable and consistent
across studies using prospective criteria or retrospective
selection. However, the studies from the UK [14] and Brazil
[5] report much higher rates. It is likely that this reflects a
scarcity of ICU beds in these countries, with less access to
intensive care for less sick patients, such as routine
postoperative patients. Indeed, comparison of overall ICU
populations between the UK and the USA, for example,
suggests that far more lower risk patients are admitted to
ICUs in the USA, with lower use of organ support, such as
mechanical ventilation, and lower mortality rates [15–19].
Thus, the ICU occurrence rates for severe sepsis are
probably higher in the UK and Brazil because the ICU beds
are reserved only for very sick patients, such as those with
sepsis and multisystem organ failure. However, at the same
time, treated incidence rates at the population level may be
lower than elsewhere.
The idea that ICU bed availability affects the incidence of
severe sepsis is probably also true for related conditions,
such as the acute respiratory distress syndrome (ARDS). A
country that aggressively manages elderly patients with
pneumonia will probably have a higher incidence of ARDS
than a country with scarce ICU beds and a philosophy of
providing less aggressive care to very elderly, moribund
patients. Using similar methodologies, a Scandinavian study224
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reported a population ARDS incidence of
13.5 cases/100,000 [20], while a US study reported a
much higher incidence of 53 cases/100,000 [21]. In the
US severe sepsis study conducted by Angus and
coworkers [12], the incidence of severe sepsis was
predominantly in the very old, such that the average age of
their cohort was 63.8 years despite the fact that they
included children and neonates. This suggests that the
USA may have many elderly ICU patients with severe
sepsis who would never be admitted to the ICU, and
consequently never develop established severe sepsis, if
they were treated in other countries.
There are five studies that generated population incidence
rates, quoting a range from 0.5 to 1.5 cases/1000 persons.
This magnitude of variation is narrower than that reported in
ICU occurrence rates if all studies are included, but
remarkably similar to the variation from 6–14 cases/100 ICU
admissions if one excludes the two very high ICU rates from
the UK and Brazil. It is also very similar to the variation in
ARDS incidence between countries. Given that approaches
for measuring these conditions have become increasingly
standardized, it seems likely that the variation is not
methodologic but rather reflects differences in treated
incidence, driven by differences in the provision of ICU
services.
In summary, in a relatively short time span, we now have a
large array of national epidemiologic studies of severe sepsis.
Although studies from developing nations are still lacking,
and although there are some differences in approaches
across studies, the most dominant feature is the consistency
of methods and findings. In most countries, about one in 10
ICU patients have severe sepsis. However, there is a
threefold variation, and some countries with much higher
rates, probably representing fewer ICU resources. The
availability of ICU resources drives the treated incidence of
severe sepsis, and variation in availability probably explains
the variation in population incidence. We would favor
adopting from oncology the terminology of treated incidence,
because this better describes the rates reported in these
studies. The next step is to address the consequences of
different treated incidence rates between countries. A higher
rate reflects more care but not necessarily better care. As we
strive to raise awareness of sepsis in the public conscience,
we must also expect debate from all sides about ‘whither to
treat’. Indeed, when thinking about the patients who might
have manifested severe sepsis if admitted to the ICU, the
words of the prominent sepsis researcher, John Marshall,
come to mind: ‘What was the old name for severe sepsis?
Natural causes.’
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